In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Mereo Biopharma Group Plc ADR (NASDAQ: MREO) closed at $2.35 down -5.62% from its previous closing price of $2.49. In other words, the price has decreased by -$5.62 from its previous closing price. On the day, 0.69 million shares were traded. MREO stock price reached its highest trading level at $2.44 during the session, while it also had its lowest trading level at $2.33.
Ratios:
For a deeper understanding of Mereo Biopharma Group Plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on December 06, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On June 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 13 ’24 when Scots-Knight Denise sold 60,046 shares for $4.22 per share. The transaction valued at 253,454 led to the insider holds 808,921 shares of the business.
Scots-Knight Denise sold 28,611 shares of MREO for $127,968 on Sep 12 ’24. The Chief Executive Officer now owns 868,967 shares after completing the transaction at $4.47 per share. On Sep 13 ’24, another insider, Lewicki John A., who serves as the Chief Scientific Officer of the company, sold 10,937 shares for $4.22 each. As a result, the insider received 46,165 and left with 78,630 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 386311776 and an Enterprise Value of 1746212224. Its current Enterprise Value per Revenue stands at 1746.212 whereas that against EBITDA is -46.595.
Stock Price History:
The Beta on a monthly basis for MREO is 0.61, which has changed by -0.21666664 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, MREO has reached a high of $5.02, while it has fallen to a 52-week low of $2.25. The 50-Day Moving Average of the stock is -15.11%, while the 200-Day Moving Average is calculated to be -36.18%.
Shares Statistics:
For the past three months, MREO has traded an average of 1.21M shares per day and 739380 over the past ten days. A total of 154.73M shares are outstanding, with a floating share count of 142.29M. Insiders hold about 8.04% of the company’s shares, while institutions hold 66.45% stake in the company. Shares short for MREO as of 1740700800 were 6360249 with a Short Ratio of 5.27, compared to 1738281600 on 6820377. Therefore, it implies a Short% of Shares Outstanding of 6360249 and a Short% of Float of 4.8600003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Mereo Biopharma Group Plc ADR (MREO) reflects the combined expertise of 6 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.01, with high estimates of $0.06 and low estimates of -$0.01.
Analysts are recommending an EPS of between -$0.02 and -$0.05 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is -$0.02, with 6.0 analysts recommending between $0.09 and -$0.06.
